Victory Capital Management Inc. Sells 6,339 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Victory Capital Management Inc. lessened its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 14.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,090 shares of the company’s stock after selling 6,339 shares during the period. Victory Capital Management Inc.’s holdings in Pediatrix Medical Group were worth $453,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Atria Investments Inc raised its position in Pediatrix Medical Group by 9.0% during the 3rd quarter. Atria Investments Inc now owns 27,124 shares of the company’s stock valued at $314,000 after purchasing an additional 2,238 shares during the last quarter. Principal Financial Group Inc. raised its position in Pediatrix Medical Group by 14.1% during the 3rd quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after purchasing an additional 63,581 shares during the last quarter. Nisa Investment Advisors LLC raised its position in Pediatrix Medical Group by 352.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 21,513 shares of the company’s stock valued at $249,000 after purchasing an additional 16,758 shares during the last quarter. Everence Capital Management Inc. bought a new position in Pediatrix Medical Group during the 3rd quarter valued at approximately $149,000. Finally, Creative Planning raised its position in Pediatrix Medical Group by 48.3% during the 3rd quarter. Creative Planning now owns 30,662 shares of the company’s stock valued at $355,000 after purchasing an additional 9,991 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Up 1.3 %

MD stock opened at $14.96 on Friday. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The business’s 50 day moving average price is $13.25 and its two-hundred day moving average price is $10.21. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.29 EPS. As a group, analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. UBS Group upped their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com downgraded Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.10.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.